Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.

Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice

Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace Directory

Revamped Web site for electrophoresis products, 7/13:108

Hoefer’s new Web site was designed to create a more positive experience with improved navigation, more product information, an enhanced storefront, and more technical literature available to download. A dealer portal section has also been added to improve the communication of support materials with channel partners. The site was designed to resize to device-display resolution, enabling a better experience for desktops, tablets, and mobile devices.

Anti-herpes, HCV panels, 7/13:107

SeraCare Life Sciences offers three new Accuvert seroconversion panels and one new Accuset performance panel. The new Accuvert seroconversion panels are HCV seroconversion panel PHV924, providing undiluted plasma samples from a single male donor of genotype 2b, drawn over an 88-day period in 2008; HCV seroconversion panel PHV925, providing undiluted plasma samples from a single male donor of genotype 1a, drawn over a 27-day period in 2008; and HCV seroconversion panel PHV926, providing undiluted plasma samples from a single male donor of genotype 3a, drawn over a 14-day period in 2009.

High-volume optical filter manufacturing facility, 7/13:106

Last year, Semrock opened a high-capacity manufacturing facility for its optical filter products. Having entered full-scale production, the company now supports its OEM customers by producing spectrally complex, hard-coated sputtered optical filters with high-volume pricing. Semrock’s products are available to the emerging diagnostic and point-of-care health care and display and sensing markets, where high-performance, miniaturized optical filters are an enabling technology.

Qiagen deals for cancer biomarkers, 7/13:107

Qiagen announced two agreements that add biomarkers involving glioblastoma, lymphoma, and other cancers to the company’s portfolio of potential companion diagnostics. In the glioblastoma project, Qiagen has entered into an exclusive worldwide licensing option with Columbia University in New York on FGFR-TACC fusion genes. Qiagen intends to develop this biomarker into a test for routine use in diagnostic workups, which may allow doctors to identify glioblastoma patients who could benefit from targeted treatments.

Cardiovascular genetic testing, 7/13

Aviir Inc. is increasing its offered services with a comprehensive inherited cardiovascular disease genetic test menu. The newly validated tests cover the major causes of cardiomyopathies, arrhythmia disorders, and other genetically transmitted diseases that affect the heart and vasculature. Each test is available for individual and familial settings. Two comprehensive panels are available to check for undiagnosed arrhythmia or cardiomyopathy.

Biosearch acquires VitraBio, DNA Technology, 7/13:106

Biosearch Technologies has acquired the oligonucleotide manufacturing division of Danish company DNA Technology and the German CPG manufacturer VitraBio. With the acquisition of DNA Technology, Biosearch adds a skilled production team with a mature quality system and an established European customer base focused in the Nordic countries.

Automated system for nucleic acid extraction, 7/13:106

Hamilton Robotics has collaborated with Macherey-Nagel to create the Genomic Starlet automated liquid handling workstation. The system extracts nucleic acids from biological samples and purifies PCR products in a non-IVD environment.

CLIA waiver studies for HIV 1/2 assay, 7/13:106

Chembio Diagnostics has commenced CLIA waiver studies for its DPP HIV 1/2 assay. In December 2012, Chembio received FDA approval for its DPP HIV 1/2 assay, which detects antibodies to HIV 1/2 in oral fluid, fingerstick whole blood, venous whole blood, serum, or plasma samples.

Beckman Coulter, Illumina automate NGS applications, 7/13:106

Through a partnership with Illumina, Beckman Coulter Life Sciences will develop, distribute, and support automation for Illumina’s TruSeq and Nextera next-gen sequencing sample preparation kits. Illumina will provide technical expertise on chemistry and protocols.

Enhanced capability for molecular diagnostic system

Abbott has introduced a new capability for its RealTime m2000 system to enhance the system’s flexibility and make molecular testing easier and more efficient. Abbott’s mPlus makes it possible for laboratories to perform molecular diagnostic tests for infectious disease detection and therapy monitoring.

MARKETPLACE

TRENDING